News | November 09, 2009

New Technology From Prescient Medical Featured at Canaccord Adams Cardiovascular Conference

November 9, 2009 — Two products from Prescient Medical, the vProtect Luminal Shield and the vPredict Optical Catheter System, will be featured at the third annual Canaccord Adams Cardiovascular Conference.

The conference will take place on Tuesday, Nov. 10 in San Francisco, and will bring together a select group of med-tech and biotech companies focused on the most important markets in cardiovascular medicine. Prescient Medical is one of only 15 development-stage private companies invited to present to potential investors at the conference.

The vProtect Luminal Shield is a novel self-expanding coronary stent system that received CE mark certification in August for use in improving coronary artery luminal diameter in patients with symptomatic ischemic heart disease. The Shield also was recently honored with Frost & Sullivan's 2009 North American Product Innovation of the Year Award. Designed specifically to minimize arterial injury and its consequences, the Shield is ideal for treating softer plaques, including plaques in patients who have recently suffered a heart attack and so-called vulnerable plaques.

Vulnerable plaques are prone to rupture, causing a release of cholesterol and cellular debris into the blood stream that often results in a clot that obstructs blood flow to the heart, thus causing a heart attack.
The vPredict Optical Catheter System is being developed for the detection and characterization of vulnerable plaque. The vPredict Optical Catheter System platform is based on Raman spectroscopy, a highly sensitive technology that is used in scores of critical non-clinical applications. The vPredict Optical Catheter System detects the clinically important compounds, including cholesterols, in the vessel wall and plaque.

"We are pleased to have our products featured at the Canaccord Adams Cardiovascular Conference," said Prescient CEO Patricia Scheller. "We believe our products have the potential to revolutionize the practice of interventional cardiology by enabling physicians to better treat and ultimately to prevent heart attacks."

For more information: www.prescientmedical.com


Related Content

News | Intravascular Imaging

March 5, 2023 — Patients with complex coronary artery disease who underwent a stenting procedure guided by intravascular ...

Home March 05, 2023
Home
News | Intravascular Imaging

June 2, 2022 — With over 30 years' experience in vascular assessment, Huntleigh, a member of the Arjo family, has ...

Home June 02, 2022
Home
News | Intravascular Imaging
February 25, 2022 – Dyad Medical, Inc., the developer of the cloud-based AI technology for cardiac image analysis called ...
Home February 25, 2022
Home
News | Intravascular Imaging

December 15, 2021 — Conavi Medical Inc. has entered into agreements for over $20 million in funding to support ...

Home December 15, 2021
Home
News | Intravascular Imaging

October 18, 2020 – New data from the PROSPECT II study shows that near-infrared spectroscopy (NIRS) intravascular ...

Home October 18, 2020
Home
Technology | Intravascular Imaging

May 20, 2019 — Philips announced the launch of the new IntraSight interventional applications platform. The secure ...

Home May 20, 2019
Home
Videos | Intravascular Imaging

Ron Waksman, M.D., associate director of the division of cardiology and director of cardiovascular research and advanced ...

Home September 26, 2018
Home
News | Intravascular Imaging

September 25, 2018 – New data demonstrate the correlation between the presence of non-flow-limiting, non-intervened-upon ...

Home September 25, 2018
Home
News | Intravascular Imaging

August 10, 2018 — Infraredx Inc. announced the Makoto Intravascular Imaging System, and accompanying Dualpro ...

Home August 10, 2018
Home
Technology | Intravascular Imaging

May 2, 2018 — Conavi Medical Inc. has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its ...

Home May 02, 2018
Home
Subscribe Now